NCT03431077 - A Study of LJPC-501 in Pediatric Patients With Hypotension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 11, 2018

Primary Completion Date

April 14, 2018

Study Completion Date

April 14, 2018

Conditions

Catecholamine-resistant Hypotension (CRH)Distributive ShockHigh Output ShockSepsis

Interventions

DRUG

Angiotensin II

Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.

Trial Locations (3)

28203

Investigational Site, Charlotte

45229

Investigational Site, Cincinnati

78207

Investigational Site, San Antonio